m6A修饰在卵巢癌中的研究进展&nbsp;

彭佳欣 张自辉 洪莉

doi:10.3969/j.issn.1006⁃5725.2023.12.020

实用医学杂志 >

2023 , Vol. 39 >Issue 12: 1577 - 1583

DOI: https://doi.org/10.3969/j.issn.1006⁃5725.2023.12.020

综述

m6A修饰在卵巢癌中的研究进展

展开

武汉大学人民医院妇产科（武汉430060）

网络出版日期: 2023-06-25

基金资助

国家重点研发计划项目子课题（编号：2018YFC 2002204）；湖北省第二届医学领军人才工程第二层次基金（编号：［2019］47）

收起

Role of m6A modification in ovarian cancer：A review of literature

Expand

Department of Obstetrics and Gynecology，Renmin Hospital，Wuhan University，Wuhan 430060，China

Online published: 2023-06-25

Fold

摘要

卵巢癌是常见的妇科恶性肿瘤，多数患者就诊时已属晚期，加之复发和化疗耐药，卵巢癌患者病死率高，预后差。m6A（N6⁃甲基腺苷）修饰是一种常见的表观遗传学修饰，可动态且可逆地调控 RNA 代谢的整个过程。近年来有多项研究表明，m6A 修饰在卵巢癌患者中表达异常，在肿瘤发生、转移和化疗耐药过程中发挥重要作用，有希望成为卵巢癌的早期诊断或评估预后的潜在肿瘤标志物，m6A 的研究也为卵巢癌治疗提供了新的思路。

关键词： 卵巢癌; m6A; 治疗靶点

本文引用格式

彭佳欣张自辉洪莉 . m6A修饰在卵巢癌中的研究进展 [J]. 实用医学杂志, 2023 , 39(12) : 1577 -1583 . DOI: 10.3969/j.issn.1006⁃5725.2023.12.020

Abstract

Ovarian cancer is a common gynecological malignancy. Most patients with the cancer are already at an advanced stage when visiting for medical consultations and are prone to recurrence and chemoresistance，so ovarian cancer patients have a high mortality rate and poor prognosis. N6 methyladenosine is a common epigenetic modification that dynamically and reversibly regulates the entire process of RNA metabolism. Recent studies have shown that m6A modification is aberrantly expressed in ovarian cancer patients，which is closely related to tumori⁃ genesis，metastasis and chemoresistance. Therefore，m6A can be used as a potential tumor marker for the early diagnosis or assessment of prognosis of ovarian cancer. The recent research of m6A also provides new ideas for the treatment of ovarian cancer. In this paper，we reviewed the role of m6A modification in ovarian cancer.

Key words： ovarian cancer; m6A; therapeutic target

Options

摘要页面

文章导航

模态框（Modal）标题

摘要

本文引用格式

Abstract